Henry I. Miller

To Deal With The Risks of Biotechnology We Need Research That Targets The Highest Type of Risk in Each Specific New Plant and Animal Product

Henry I. Miller

Is a medical researcher and columnist, formerly with the FDA, the Robert Wesson Fellow in Scientific Philosophy and Public Policy at Stanford University's Hoover Institution, a public policy think tank located on the university's campus in California.




Miller was born on July 1, 1947 in South Philadelphia and raised there.

He was educated at M.I.T. (B.S. in Life Sciences) and the University of California, San Diego (M.Sc. and M.D.) and was a Clinical Fellow in Medicine and intern and resident at Beth Israel Deaconness Hospital. He performed research on gene organization and expression as a Research Fellow in the laboratory of Dr. Philip Leder at the National Institutes of Health and is the co-discoverer of the RNA-dependent RNA polymerase in influenza ("flu") virus.[2]

Miller was a civil servant for fifteen years at the US Food and Drug Administration (FDA). He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and was instrumental in the rapid licensing of genetically engineered human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government.

Since coming to the Hoover Institution, Miller has been a prolific author of books and articles in scholarly journals, newspapers and online.

On 10 Sep 2014, Henry Miller wrote that there are far higher priorities to spend money on than Ebola.[3]

Seven days later on 17 Sep 2014, President Obama announced that the US would lead the effort against Ebola in Africa by spending $500 million and sending troops .

Click To Order Book